Sökning: "sIL-2R"
Hittade 4 avhandlingar innehållade ordet sIL-2R.
1. Monoclonal antibodies and cytokines for therapy of patients with advanced colorectal carcinoma : a clinical and immunological study
Sammanfattning : There is a great need for developing and improving treatment alternatives in colorectal carcinoma (CRC). The tumour associated antigen (TAA) GA733/CO17-1A is expressed by more than 90% of all CRCs, on the majority of both primary and metastatic CRC cells. LÄS MER
2. Cytokine production in allogeneic haematopoietic stem-cell transplantation patients
Sammanfattning : Severe immunological complications may occur after haematopoietic stem-cell transplantation (HSCT). These include acute graft-versus-host disease (GVHD), veno-occlusive disease of the liver (VOD) and severe infections. LÄS MER
3. Immune moldulatory effects of intravenous immunoglobulin in vitro and after allogeneic bone marrow transplantation
Sammanfattning : Intravenous immunoglobulin (IVIG) has been used in patients with immunodeficiencies and various autoimmune diseases. Its immune modulatory effect is well documented. In allogeneic bone marrow transplantation (BMT) IVIG has been used to reduce the incidence of infections and graft-versus-host-disease (GVHD). LÄS MER
4. Polyneuropathy associated with monoclonal gammopathy : A clinical, neurophysiological and immunological study
Sammanfattning : This thesis is based upon clinical, neurophysiological, and immunological studies of polyneuropathy (symmetrical impairment of sensory and motor nerve function) in patients with monoclonal gammopathies, that is, patients characterized by proliferation of a plasma-cell clone secreting homogeneous immWloglobulins (M-component), which in some patients has serum antibody reactivity against peripheral nerve myelin.The prevalence of clinical polyneuropathy in patients with monoclonal gammopathy (n=3) was 36%, and the prevalence of all forms of polyneuropathy including patients with neurophysiological signs only andpatients with probable polyneuropathy (signs but no symptoms) was 58%. LÄS MER